Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 8/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 7/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 6/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 6/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 9/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129279 | 1.00 | HDAC3 (1.00) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL13949836 | 0.93 | HDAC3 (0.87) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL13949887 | 0.93 | HDAC1 (0.86) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL8245439 | 0.88 | HDAC1 (0.79) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL13949796 | 0.87 | HDAC1 (1.00) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL13949807 | 0.86 | HDAC1 (0.80) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL8242464 | 0.86 | HDAC1 (0.75) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL8241707 | 0.86 | HDAC1 (0.86) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL13949823 | 0.86 | HDAC1 (0.77) | HDAC3HDAC6HDAC1HDAC4HDAC7 | |
| SCHEMBL5128429 | 0.85 | HDAC1 (1.00) | HDAC3HDAC6HDAC1HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015085860-A1 | HETEROCYCLIC HYDROXAMIC ACID COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 广州康缔安生物科技有限公司 | 2015-06-18 | — | — | WO | disclosed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1870399-A1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| EP-1318980-B1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| US-20060189674-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2006-08-24 | — | — | US | disclosed |
| US-7067551-B2 | Deacetylase inhibitors | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | SECURA BIO, INC. | 2005-04-21 | — | — | US | disclosed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | disclosed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6552065-B2 | Antiproliferative agents | NOVARTIS AG (CH) | 2003-04-22 | — | — | US | disclosed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | disclosed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085507-A1 | p-phenylethenyl hydroxamates; anticarcinogenic, antitumor, antiproliferative agents; regulating p21 promoter; improved stability | TP53, CDKN1A, HDAC1 | HDAC3 16/4885HDAC6 45/4885HDAC1 3/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC3 2/4885HDAC6 3/4885HDAC1 1/4885 |
| US-20060189674-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC3 2/4885HDAC6 3/4885HDAC1 1/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC3 2/4885HDAC6 3/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.